Exonics logo.jpg
Exonics Announces Publication of Research Demonstrating Gene Repair Technology Restored Dystrophin Expression in Canine Model of Duchenne Muscular Dystrophy
August 30, 2018 14:00 ET | Exonics Therapeutics
Systemic delivery of SingleCut CRISPR gene editing components restored dystrophin expression to up to 92 percent of normal expression in heart muscle in canines First study of Exonics’ SingleCut...
Exonics logo.jpg
Exonics Therapeutics Appoints Roger M. Perlmutter, M.D., Ph.D., to Board of Directors
January 30, 2018 08:00 ET | Exonics Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne...
Exonics logo.jpg
Exonics Therapeutics Raises $40 Million in Series A Financing 
November 08, 2017 07:30 ET | Exonics Therapeutics
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne...
Exonics logo.jpg
Exonics Therapeutics Launches with Funding from CureDuchenne Ventures to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
February 27, 2017 07:30 ET | Exonics Therapeutics
BOSTON, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently correct a...